Brown Advisory Inc. Lowers Position in Organon & Co. (NYSE:OGN)

Brown Advisory Inc. reduced its stake in Organon & Co. (NYSE:OGN) by 8.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 34,923 shares of the company’s stock after selling 3,256 shares during the quarter. Brown Advisory Inc.’s holdings in Organon & Co. were worth $504,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of OGN. Lindbrook Capital LLC raised its position in Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock valued at $27,000 after buying an additional 1,428 shares during the last quarter. Harvest Fund Management Co. Ltd increased its position in shares of Organon & Co. by 495.5% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Gladius Capital Management LP increased its position in shares of Organon & Co. by 65.1% during the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after purchasing an additional 858 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Organon & Co. during the 3rd quarter valued at $35,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Organon & Co. during the 4th quarter valued at $38,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Down 1.7 %

OGN stock opened at $20.99 on Monday. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. The company has a market capitalization of $5.40 billion, a price-to-earnings ratio of 5.13, a PEG ratio of 0.91 and a beta of 0.81. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The stock has a fifty day moving average of $19.14 and a 200-day moving average of $16.47.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.31. The company had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. As a group, equities research analysts predict that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be paid a dividend of $0.28 per share. The ex-dividend date is Friday, May 10th. This represents a $1.12 annualized dividend and a dividend yield of 5.34%. Organon & Co.’s payout ratio is 27.38%.

Analyst Ratings Changes

OGN has been the subject of several research analyst reports. Piper Sandler raised their target price on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th. The Goldman Sachs Group raised their target price on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.